Current Report Filing (8-k)
November 04 2021 - 8:21AM
Edgar (US Regulatory)
0000849636
false
0000849636
2021-11-04
2021-11-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 4, 2021
RESPIRERX
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
1-16467
|
|
33-0303583
|
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S
Employer
Identification
No.)
|
|
126
Valley Road, Suite C
Glen
Rock, New Jersey
|
|
07452
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (201) 444-4947
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01 Regulation FD Disclosure
On
November 4, 2021, RespireRx Pharmaceuticals Inc. (the “Company”) announced that a video interview of the Company’s
Senior Vice President, Chief Financial Officer, Treasurer and Secretary, Jeff E. Margolis by Proactive Investors will be made available
initially and to the general public on November 4, 2021.
The
video interview may be accessed at https://youtu.be/tCvvUlN7N7M.
The
interview will appear on the Proactive Investors website homepage throughout the day on Thursday, November 4, 2021 at www.proactiveinvestors.com
and thereafter on the Proactive Investors website by searching for RespireRx at https://www.proactiveinvestors.com/proactive_live
and will also be available via link from RespireRx’s website at www.respirerx.com.
The
press release announcing the Company’s participation in the conference is attached as Exhibit 99.1.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
A
list of the exhibit that is furnished and not filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere
in this document, and is incorporated herein by reference.
EXHIBIT
INDEX
*
Furnished herewith.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
Date:
November 4, 2021
|
RESPIRERX
PHARMACEUTICALS INC.
|
|
|
|
|
|
|
By:
|
/s/
Jeff E. Margolis
|
|
|
|
Jeff
E. Margolis
|
|
|
|
Vice
President, Treasurer and Secretary
|
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Dec 2024 to Jan 2025
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jan 2024 to Jan 2025
